"bharat-biotech"

Hyderabad-based vaccine maker to supply 20 million doses of Covaxin during the second and third quarters of 2021

The representatives from the Central Asian nation of 41 million people took a tour of the world-class Bio-Safety Level 3 manufacturing facility.

Life sciences sector in Telangana attracted investments to the tune of about Rs 3,700 crores in last one year with an employment potential for around 14,000 people

This year's edition to be held virtually

Dr Krishna M Ella, CMD and Suchitra Ella, joint managing director, Bharat Biotech International will receive the award on February 22, during the inaugural event of BioAsia 2021.

2,77,825 inoculated as first phase of vaccine drive in State concludes

Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.

The vaccination scheme will help contain and lead the nation towards accomplishing a Covid-19 disease-free India.

Krishna M Ella, Bharat Biotech, CMD, said, “With prior expertise in malaria research, WHO prequalified vaccines, supplied to more than 70 countries, Bharat Biotech is geared up for large-scale manufacturing.

Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

This is India's first and only phase-3 efficacy study for a Covid-19 vaccine, and the largest phase-3 efficacy trial ever conducted for any vaccine in the country.

The company was given a fresh letter of comfort recently for supplying another 45 lakh doses of Covaxin. The doses will be dispatched as when the Ministry places orders with the company

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects caused by the vaccine administered while in the clinical trial mode

Zilla Parishad Chairperson Roja Sharma was speaking after launching the vaccination drive at Area Hospital, Siddipet on Saturday

Hyderabad: Governor Dr Tamilisai Soundararajan on Saturday launched the Covid vaccination programme for the frontline workers at Nizam’s Institute of Medical Sciences (NIMS). She appealed to all the frontline warriors and others to take the vaccine with confidence as the vaccines were developed and cleared as per strict safety norms adhering to international standards. “Our […]

58 healthcare centres ready to provide emergency services to individuals with Adverse Events Following Immunisation across State

After having received the government purchase order for 55 lakh doses, Bharat Biotech shipped the first batch of vaccines (each vial containing 20 doses) to Gannavaram, Guwahati, Patna, Delhi, Kurukshetra, Bengaluru

"Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects are negligible"

The supplies of Covaxin will be prioritised for public market through direct procurement by Brazil government while the supplies to private market would be based upon receipt of market authorisation from the country's regulator

The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.